Pharmacologic properties of (-)-3PPP (preclamol) in man.

Abstract

The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar "rising dose" placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.

• Authors: C A Tamminga, N G Cascella, R A Lahti, M Lindberg, A Carlsson
• Journal: Journal of neural transmission. General section (J Neural Transm Gen Sect) Vol. 88 Issue 3 Pg. 165-75 ( 1992) Austria
• PMID: 1358119 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Dopamine Agents
• Piperidines
• preclamol

Topics

• Administration, Oral
• Adult
• Chromatography, Gas
• Dopamine Agents (adverse effects, pharmacokinetics, therapeutic use)
• Double-Blind Method
• Half-Life
• Humans
• Injections, Intramuscular
• Male
• Piperidines (adverse effects, pharmacokinetics, therapeutic use)
• Psychiatric Status Rating Scales
• Schizophrenia (drug therapy)
• Schizophrenic Psychology